Status: Recruiting
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
This is a dose-escalation open-label Phase 1/2a study. The purpose of this first-in-human study is to assess the safety and tolerability of LEU011 (autologous CAR T cells targeting NKG2D ligands) in patients with solid tumours.
Participants needed: 17
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Leucid BioUpdated: Aug 31, 2026Locations: 2
Eligibility criteria
Histologically and/or cytologically confirmed solid tumour. [+20]
Central nervous system (CNS) involvement by malignancy unless (i) have completed... [+14]